Market Overview

Morgan Stanley Reiterates Overweight Rating on Watson Pharmaceuticals


In a report published Monday, Morgan Stanley reiterated its Overweight rating on Watson Pharmaceuticals (NYSE: WPI).

Morgan Stanley noted, “We did not know that Covidien was pursuing generic Concerta (we were not aware of any Paragraph IV litigation), nor that it would qualify for exclusivity on the 27, 36, and 54 mg doses (85% of total franchise IMS sales). The 27 mg dose (15% of sales) launches immediately, and Covidien plans to launch the 36 and 54 mg doses (70% of sales) in 1Q:13. According to Covidien's press release, exclusivity is triggered upon commercial launch of each respective dose.”

Watson Pharmaceuticals closed on Friday at $89.04.

Latest Ratings for WPI

Jan 2013DowngradesBuyNeutral
Nov 2012MaintainsOutperform
Nov 2012UpgradesNeutralOverweight

View More Analyst Ratings for WPI
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (WPI)

View Comments and Join the Discussion!

Latest Ratings

PNRJefferiesInitiates Coverage On
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Wedbush Securities Reiterates Neutral Rating, Lowers PT on Family Dollar Stores

UPDATE: BGC Financial Reiterates Buy Rating, Raises PT on eBay